Study Details

Back to Search Results

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02014558

Astellas Study ID

The unique identification code given by the study sponsor.

2215-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Leukemia - AML

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Oct 2013 - Mar 2018

Masking

None (Open Label)

Enrollment number

265

A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US10007

Nashville, United States, 37232

Site US10012

Baltimore, United States, 21201

Site US10009

New York, United States, 10022

Site US10026

Fairfax, United States, 22031

Site DE49002

Berlin, Germany, 12203

Site IT39001

Bologna, Italy, 40138

Site US10016

Stanford, United States, 94305

Site US10005

San Francisco, United States, 94143

Site FR33002

Pessac, France, 33604

Site US10002

Houston, United States, 77030

Site US10023

Scottsdale, United States, 85259

Site DE49001

Ulm, Germany, 89081

Site DE49005

Marburg, Germany, 35043

Site US10008

Los Angeles, United States, 90095-1678

Site US10004

Philadelphia, United States, 19104

Site FR33001

Angers, France, 49033

Site US10001

Chicago, United States, 60611

Site US10017

Charleston, United States, 29425-8900

Site DE49003

Magdeburg, Germany, 39120

Site US10014

Cleveland, United States, 44195

Site FR33003

Grenoble Cedex, France, 38043

Site US10018

Hershey, United States, 17033

Site US10024

Jacksonville, United States, 32224

Site US10021

Birmingham, United States, 35294

Site US10019

New York, United States, 10065

Site US10022

Duarte, United States, 91010

Site US10010

Buffalo, United States, 14263

Site US10003

Baltimore, United States, 21287

Site US10013

New York, United States, 10032

Site US10015

Chicago, United States, 60637

Site US10011

Rochester, United States, 55905

Site DE49004

Dresden, Germany, 01307

Site US10020

Hackensack, United States, 07601

Site US10006

Minneapolis, United States, 55455

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo